Sucampo (Mallinckrodt) Wins Challenge to Patent Covering its Registered Drug

22 September 2020

On February 14, 2019, the Chamber for patent disputes ruled in favor of our client – a patent-holding company Sucampo AG – in a patent invalidation case. 

Rospatent's decision was appealed to the Intellectual Property Court. In its hearings held on September 22, 2020, the court rejected the claims, affirming the validity of Sucampo's patent. The patent is related to lubiprostone, a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation.

The client was represented by Sojuzpatent attorneys and lawyers in both instances.

Sucampo Pharmaceuticals, Inc. (USA), an important biopharmaceutical company, was acquired by Mallinckrodt Pharmaceuticals in 2018.